Roginolisib hemifumarate

• CAT Number: I045752
• CAS Number: 1621688-31-0
• Molecular Formula: C26H27FN4O5S.1/2C4H4O4
• Molecular Weight: 584.62
• Purity: ≥95%
• IUPAC Name: (E)-but-2-enedioic acid;[6-fluoro-1-[4-(morpholin-4-ylmethyl)phenyl]-5,5-dioxo-4H-thiochromeno[4,3-c]pyrazol-3-yl]-morpholin-4-ylmethanone
• InChI: InChI=1S/2C26H27FN4O5S.C4H4O4/c2*27-22-3-1-2-20-24-21(17-37(33,34)25(20)22)23(26(32)30-10-14-36-15-11-30)28-31(24)19-6-4-18(5-7-19)16-29-8-12-35-13-9-29;5-3(6)1-2-4(7)8/h2*1-7H,8-17H2;1-2H,(H,5,6)(H,7,8)/b;;2-1+
• InChIKey: GSMZEFQGEJPDES-WXXKFALUSA-N
• SMILES: C1COCCN1CC2=CC=C(C=C2)N3C4=C(CS(=O)(=O)C5=C4C=CC=C5F)C(=N3)C(=O)N6CCOCC6.C1COCCN1CC2=CC=C(C=C2)N3C4=C(CS(=O)(=O)C5=C4C=CC=C5F)C(=N3)C(=O)N6CCOCC6.C(=C/C(=O)O)\C(=O)O

Roginolisib hemifumarate（Cat No.:I045752）is an orally active, selective inhibitor of phosphoinositide 3-kinase gamma (PI3Kγ), an enzyme involved in immune cell signaling and tumor microenvironment modulation. By blocking PI3Kγ activity, roginolisib disrupts pathways that promote cancer cell survival, immune suppression, and inflammation. The hemifumarate salt enhances solubility and bioavailability, making it suitable for clinical investigation. Researchers study roginolisib hemifumarate as a potential therapeutic for solid tumors, hematological malignancies, and inflammatory diseases, highlighting its promise in targeting PI3K-driven pathological processes with improved specificity and efficacy.